Portuguese drug candidate to be developed in China
Technophage, a start-up biotech located at Instituto de Medicina Molecular, and the Chinese Shanghai Institute of Materia Medica signed a collaboration agreement to start pre-clinical and clinical tests of a biological product developed by Technophage. TA_101 is a drug candidate for the treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis.